OTLC News and Press, Oncotelic Therapeutics Inc From 09/04/23

Oncotelic Therapeutics Inc (OTLC) is expected to report $0 for Q2 2023

AGOURA HILLS, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today it was featured in Life Sciences Review, Cancer Immunology Edition and has been awarded a Top Cancer Immunotherapy Solution...

AGOURA HILLS, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its joint venture partner, GMP Biotechnology Limited’s wholly owned subsidiary – Sapu Bioscience, LLC (ȁ...

AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), annouces the beta unveiling of a pioneering press releases (“PR”) chatbot. This chatbot is set to redefine user interaction b...

AGOURA HILLS, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“ Oncotelic ” or the “Company”) (OTCQB:OTLC), a pioneering developer of therapeutic interventions for rare and orphan diseases such as Parkinson's Disease and vario...

AGOURA HILLS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), , today announced the beta launch of a proprietary SEC chatbot, utilizing our DAO token (PDAO) and Artificial Intelligence (AI). This chat...

2023-04-19 13:34:05 ET Oncotelic Therapeutics ( OTCQB:OTLC ) is collaborating with Vectara , to accelerate the development of new therapies to treat cancer, infectious disease, and aging using Large Language Model (LLM) technology. A LLM is an artificial intelligence (AI) sys...

The companies are executing on the shared vision of utilizing AI for effective knowledge management in the pharmaceutical research and development industry. AGOURA HILLS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ”...

2023-04-17 08:00:31 ET Oncotelic Therapeutics press release ( OTCQB:OTLC ): FY net income of $4.67M For further details see: Oncotelic Therapeutics reports FY results

AGOURA HILLS, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) ( OTCQB: OTLC ) is providing a summary of its financial results...